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ABSTRACT
The MITOMAP (http://www.mitomap.org) data sys-
tem for the human mitochondrial genome has been
greatly enhanced by the addition of a navigable
mutational mitochondrial DNA (mtDNA) phyloge-
netic tree of 3000 mtDNA coding region sequences
plus expanded pathogenic mutation tables and a
nuclear-mtDNA pseudogene (NUMT) data base. The
phylogeny reconstructs the entire mutational his-
tory of the human mtDNA, thus defining the mtDNA
haplogroups and differentiating ancient from recent
mtDNA mutations. Pathogenic mutations are classi-
fied by both genotype and phenotype, and the
NUMT sequences permits detection of spurious
inclusion of pseudogene variants during mutation
analysis. These additions position MITOMAP for the
implementation of our automated mtDNA sequence
analysis system, Mitomaster.
INTRODUCTION
MITOMAP is a comprehensive database of human mtDNA
variation and its relation to human evolution and disease.
The need for a curated and thus reliable database of mitochon-
drial gene sequence variation with easily used web-based
query tools is becoming increasingly essential as the impor-
tance of mtDNA variation in the common age-related meta-
bolic and neurodegenerative diseases, aging and cancer is
elucidated. The mtDNA encompasses the 13 core polypeptide
genes that deﬁne the efﬁciency of the mitochondrial energy
generating system oxidative phosphorylation (OXPHOS), the
tRNAs and rRNAs for their expression, and a 1121 np control
region that regulates mtDNA transcription and replication.
The mtDNA also has a unique genetics, being maternally
inherited, present in thousands of copies per cell, and capable
of encompassing various percentages of mutant and normal
molecules (or heteroplasmy) (1) . Hence, the mtDNA imparts
a quantitative genetics to the vital, systemic function of energy
production (1,2).
The 16569 nt pairs (np) of the closed circular mtDNA are
each numbered sequentially and the ‘standard’ base at each
position (3) is speciﬁed in the ‘revised Cambridge Reference
Sequence’ (rCRS), GenBank J01415.2. This permits any new
mtDNA sequence to be unambiguously deﬁned by specifying
only the deviant positions and bases relative to the rCRS.
Thus, all of the information in MITOMAP can be digitally
interrelated.
The human mtDNA has a very high mutation rate, and this
has generated three classes of sequence variants: pathogenic,
adaptive and neutral. Pathogenic mutations damage con-
served gene functions and as the deleterious mutation
increases in its percentage heteroplasmy, it erodes systemic
cellular energy output. This deﬁciency is acted on by natural
selection and the mutation is soon eliminated from the popu-
lation as hereditary disease. Hence, all deleterious mutations
in the population are relatively recent. Adaptive mtDNA
mutations also alter conserved functions but these alterations
are advantageous in certain environments. Consequently, they
become established in the individual (or homoplasmic) and
increase in the population that occupies the compatible envi-
ronment. Neutral mutations accumulate by chance, but those
linked to advantageous mutations can become enriched in
particular populations by hitchhiking.
Mutations in the mtDNA not only arise in the female germ-
line, but also accumulate in the post-mitotic cells of the body
with age. These somatic mtDNA mutations now appear to be
the aging clock and may also be important in the etiology of
certain cancers (1,2).
Pathogenic mtDNA mutations can be divided into those
that alter more than one gene (inter-gene or contiguous
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doi:10.1093/nar/gkl927gene defects) and those that affect only one gene (intra-gene
or single gene defects). All contiguous gene defects invol-
ve rearrangement (insertion-deletion) mutations. Intra-gene
mutations include small insertion-deletion mutations or base
substitution mutations. The intra-gene mutations can either
alter polypeptide coding genes or protein synthesis (rRNA
and tRNA) genes. The functional severity of pathogenic nuc-
leotide substitutions can be estimated, in part, through the
inter-species conservation index (CI) and for rRNA or tRNA
genes by the effect of the base change on the RNA secondary
structure. Since the clinical effect of a mutation is the product
of both the severity of the mutation and its percentage of het-
eroplasmy, the clinical phenotypes of heteroplasmic mtDNA
mutations can be highly variable among the maternal rela-
tives (1,2). Since mtDNA mutations can arise in both the
germline and somatic tissues, they have been associated
with both degenerative diseases and cancers (4–6).
Adaptive mutations alter functions and thus are primarily
single nucleotide substitution mutations. Moreover, since
they are retained in the population by selection, they are fre-
quently ancient and present at polymorphic frequencies.
About 25% of the polypeptide amino acid substitution (mis-
sense) mutations present in the human mtDNA phylogenetic
tree are adaptive (7,8), 10–20% of tRNA mutations appear
to be adaptive, as do various rRNA variants (9). Many of
these same mutations have also been reported as somatic
mutations in cancer cells suggesting that tumors adapt to
their changing energetic environment through the evolution
of mtDNA variation (10). A surprisingly high proportion of
cancer control region somatic mutations are also population
polymorphisms (10), suggesting that modulation of mtDNA
replication and transcription is an important adaptive
strategy.
Since mtDNA mutations accumulate sequentially along
maternal mtDNA lineages, the mtDNAs of region-speciﬁc
branches of the mtDNA tree are founded by a common
mtDNA haplotype and thus share a set of common polymor-
phisms. From this founder, additional mutations are added
sequentially over time forming groups of related haplotypes
is called a haplogroup. Since selection may have caused the
haplogroup to ﬂourish in the new environment, different
haplogroups may be functionally different (8,9). Evidence
that haplogroups can be functionally different comes from
the fact that haplogroups are associated with predilection to
or protection from various clinical phenotypes. For instance,
haplogroup J increases the risk of developing blindness in
association with the milder Leber Hereditary Optic Neuropa-
thy (LHON) mutations (11–13) and haplogroup T increases
risk for depression (14). However, other haplogroups are pro-
tective against Alzheimer Disease (15–17) and Parkinson
Disease (17–19) and are associated with increased longevity
(8,20–24).
Throughout the evolution of the symbiosis between the
nuclear-cytosol and the mitochondrial organisms, sequences
from the mtDNA have been transferred to the nDNA with
the result that the vast majority of mitochondrial genes are
now located in the nucleus. The transfer of mtDNA sequences
to the nDNA continues today, but differences in the mtDNA
genetic code that arose prior to the origin of the fungal-
animal mtDNA lineage render the mtDNA sequences unintel-
ligible to the nuclear-cytosol system (2). Consequently, all
recent mtDNA transfers into the human nDNA have resulted
in nuclear-mtDNA pseudogenes (NUMTs) (25). NUMTs are
potentially problematic since they can be inadvertently ampli-
ﬁed using the polymerase chain reaction (PCR), sequenced,
and the pseudogene variants mistaken for pathogenic
mtDNA mutations (26,27).
While the mtDNA retains the 13 central OXPHOS proton
and electron carries for the OXPHOS circuitry, all of the
structural genes necessary to assemble the mitochondrial
OXPHOS complexes as well as all of the genes needed to cre-
ate a mitochondrion are now encoded by the nucleus, a total
of 1500 mitochondrial genes. Therefore, many mutations
that affect mitochondrial function are the result of nDNA
mutations (1,2).
A mtDNA SEQUENTIAL MUTATION
PHYLOGENETIC TREE
A number of factors must be considered when evaluating
the nucleotide variants observed in a new mtDNA sequence
relative to the rCRS. These include the association between
different variants on particular branches of the mtDNA tree
(the haplogroup), the time in human mtDNA radiation that
the variant appeared and the position of the variant in the pro-
tein or RNA gene. All of these considerations were utilized in
developing our sequential mutational phylogenetic tree of the
human mtDNA.
Our mtDNA tree encompasses the information in 2959
mtDNA coding region sequences, using the rCRS (GenBank
J01415.2) as the reference. While our tree was assembled
primarily using mtDNA coding region single nucleotide poly-
morphisms (SNPs), informative control region SNPs are also
being incorporated when available. However, this dataset is
incomplete since the control region sequences have not
been reported for many of the published mtDNA sequences
used in building the tree. Each sequence was analyzed for
possible sequencing errors, identiﬁed by base changes incon-
sistent with the most likely haplogroup. Sequences with mul-
tiple potential errors were not included in the dataset. Our tree
is now available in MITOMAP, http://www.mitomap.org.
Partial representations of the tree are presented in Figure 1.
The core topology of the tree was generated by the
neighbor-joining program from MEGA (28) using 1060
human mtDNA sequences. The branching order used is
highly robust as demonstrated by its consistency within
1000 bootstrap iterations. Separate neighbor-joining trees
were also built for each major haplogroup, again with the
branching order being robust based in 1000 bootstrap itera-
tions. Then using sequence alignment and sequence compar-
isons, the positions of the individual nucleotide changes were
incorporated into the various branches and nodes of the tree.
Since the core tree encompasses all of the major mtDNA
haplogroups, new mtDNA sequences can be continually
incorporated into the existing tree manually without necessity
for further computer analysis. Atypical variants such as
insertion-deletions are also added manually and unsolved
parallel mutations are resolved by network analysis.
The overall branching order of the human mtDNA tree
has been clear for many years (29–32). However, the pres-
ence of identical mutations in multiple different parts of the
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concluded that many of these recurrent mutations were due to
convergent evolution resulting from adaptive selection acting
on speciﬁc functional variants (8,9).
The major branches of the tree are labeled with alphabeti-
cal letters. The letters were assigned as the mtDNA lineages
became apparent. Because Native Americans were found to
have a limited number of mtDNA lineages (33), the four
major Native American haplogroups were designated A, B,
C and D (34,35). Subsequent analysis added haplogroups in
Europe (H, I, J, T, U, Uk, V, W and X) (36,37), Asia
(many derivatives of macro-haplogroups M and N which
radiated out-of-Africa) (38,39) and Africa (haplogroups L0,
L1, L2 and L3) (7,40,41). A ﬁfth Native American haplo-
group was also found to be related to Eurasian mtDNA
haplogroup X (42). The sub-branching order of the haplo-
groups has been further reﬁned by incorporating subsequent
nomenclatural proposals (43) and application of the informa-
tion derived from complete mtDNA sequences (7,44,45).
Since the African mtDNAs lie at the root of the mtDNA
phylogeny (29–31), the African haplogroups are presented
at the beginning (top) of the phylogenetic tree (Figure 1).
The complete phylogeny with all of the ordered SNPs
requires 126 pages to print. To make the tree more accessible,
it was integrated and transferred into the Canvas X (ACD
Systems, Inc.) program. The PDF ﬁle was then exported to
http://www.mitomap.org/. In this form, the entire tree can
be viewed at any resolution desired, from ultra-low resolu-
tion, where all of the branches can be observed but no detail
can be perceived, to ultra-high resolution, where the branch-
ing order is lost but the individual nucleotide changes can be
seen (Figure 1).
The nucleotide position of each change is located in the
tree in the order that they arose, and the nature of the muta-
tion, transition versus transversion, given. If the nucleotide
change alters a tRNA or an rRNA gene, the mutation is pre-
sented in green with the gene designated. If the mutation
alters a polypeptide gene, but is synonymous, then it is pre-
sented in red with the gene identiﬁed. However, if the muta-
tion alters the amino acid sequence of a polypeptide gene, the
mutation is presented in black with the affected gene identi-
ﬁed and the codon position and amino acid substitution
reported. Non-coding variants are shown in blue, and few
representative pathogenic mutations are included in the tree
Figure 1. (A) Sequential mutational phylogenetic tree of 2959 mtDNA coding region sequences. The full tree is available in PDF format at http://www.mitomap.
org/mitomap-phylogeny.pdf. All mutations are transitions except where indicated. Black polymorphisms represent nonsynonymous mutations (amino acid,
position, amino acid, gene), red synonymous mutations (gene), green tRNA or rRNA mutations (gene), blue indicates non-coding nucleotides in the coding
region and underlined yellow represent pathological mutations. Large blue letters indicate a haplogroup designation and large black letters allow for navigation of
the tree at low magnification. Numbers in black below the final polymorphism are the bibliographic references and sequence identifiers. For example, 4(55)
indicates Howell’s article (4 is the code for this article) and 55 is the number of the sequence in the article). The bibliographic references are available on the
mitomap website. (B) Magnification of blue box in Figure1A showing details of the tree for subhaplogroup J2b.
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changes, their relationship to each other and their potential
signiﬁcance can easily be observed.
Because of how our tree was developed, it is invaluable for
analyzing the nature of the nucleotide differences found in
any new mtDNA sequence relative to the rCRS. By tracing
the nucleotide variants in the new mtDNA sequence along
the branching order of our tree, the new sequence’s hap-
logroup is deﬁned, the time that each variant arose (ancient
versus recent) is determined and the effect of the sequence
variant on the polypeptide or RNA gene revealed.
Ancient functional variants associated with a new sequence
may be adaptive variants and may have also arisen indepen-
dently in other branches of the phylogeny. Many of these
have already been identiﬁed and discussed (8,9). Variants
that do not appear in our phylogenetic tree are likely to be
relatively recent mutations. If the mtDNA sequence is from
a potentially maternally inherited disease patient and the
new mutation is potentially functionally signiﬁcant, the muta-
tion becomes a candidate for a pathogenic mutation. Neutral
variants can be either ancient or recent, but do not alter an
important mitochondrial function.
With these rules, a mtDNA sequence from a patient with a
potentially maternally inherited disease would be analyzed by
ﬁrst comparing the sequence to the rCRS, and all differences
will be listed. These variants would then be used to trace
down the various branches of the phylogenetic tree until
you arrive at the end of a terminal branch. All sequence vari-
ants that have been used thus far are haplogroup-associated
polymorphisms. Any variants that are left over must be recent
and require additional analysis. If a residual nucleotide
change alters an amino acid in a mtDNA polypeptide or the
sequence of a tRNA or rRNA, then it is a candidate for a
pathogenic mutation. For polypeptide mutations, calculation
of the CI of the variant amino acid can give further insight
into pathogenicity (8). Similarly, for a tRNA or rRNA
sequence change, if the variant alters a conserved nucleotide
and/or affects the secondary structure of the RNA then it
becomes a candidate for a pathogenic mutation (9). Addi-
tional criteria suggesting pathogenicity could include the
presence of heteroplasmy and a correlation between the
severity of the pathogenic mutation and the percentage of
mutant mtDNAs present in various family members along a
maternal lineage. Another criterion could be the similarity
between the pathological presentation of the mutation and
that of a similar type of pathogenic mutation that presents
with a similar phenotype.
In certain cases, multiple patients from unrelated families
may be found that have closely related mtDNA haplotypes.
In these situations, it is possible that the background
mtDNA haplogroup is also contributing to the pathogenicity
of the deleterious mutation. This type of phenomenon has
been documented for the milder pathogenic mutations at nt
G11778A, T14484C, and T10663C which cause LHON,
which are preferentially associated with mtDNA haplogroups
J and T (11–13).
PATHOGENIC MTDNA MUTATION TABLES
One strong criterion for identifying a pathogenic mtDNA
mutation would be if the same mutation had been identiﬁed
in other patients with similar clinical presentation. To facili-
tate this type of comparison, the MITOMAP mutational
tables have been completely updated and upgraded. The
current searchable tables are divided into three major classes:
(i) mutations associated with LHON, (ii) mutations that affect
polypeptide sequences but present with other phenotypes and
(iii) mutations that alter tRNAs and rRNAs and present with a
various multi-system clinical problems. These tables and the
associated clinical diseases are explained in depth in our vari-
ous clinical reviews (2,46,47). As an example, the LHON dis-
ease mutations have been sub-classiﬁed into two main
categories. The ﬁrst category includes well characterized
and causative mutations designated the ‘top 10’ primary
LHON mutations. This group includes the three most com-
mon LHON mutations (G3460A, G11778A and T14484C)
with account for 95% of LHON patients. The second muta-
tion category includes mutations that have been reported in a
single family and thus require additional independent reports
to conﬁrm their causal association with LHON.
If in the process of analyzing an mtDNA sequence from a
patient, one of the recent sequence differences is also present
in one of the pathogenic mutational tables, then this mutation
becomes a good likely candidate for the disease mutation.
However, it must be remembered that the mtDNA haplogroup
background can be a contributing factor in some diseases
such as LHON. Hence, it is important that the role of the
mutation be considered in the larger context of what we
know about human mitochondrial genetics (2).
MITOCHONDRIAL DISEASES OF
NUCLEAR GENETIC ORIGIN
While the mtDNA encodes 37 critical genes for OXPHOS
(13 polypeptides, 22 tRNAs and 2 rRNAs) the nDNA
encodes in the order of 1500 additional mitochondrial pro-
teins and mutations in these genes can also cause mitochon-
drial disease. Hence, many of the more severe mitochondrial
diseases can be caused by mutations in nDNA encoded genes
for the structural or assembly proteins of the OXPHOS com-
plexes and a spectrum of disorders can result from nDNA
mutations that affect mtDNA replication (48). To alert
MITOMAP users to these important classes of mitochondrial
disease, MITOMAP now includes summary tables of the
known nDNA-encoded mitochondrial diseases (2).
NUMT PSEUDOGENE DATABASE
The nDNA also encodes 247 fragments of the mtDNA of
sufﬁciently recent origin to be easily mistaken for legiti-
mate mtDNA sequences. Inadvertent PCR ampliﬁcation of
one of these sequences during a clinical study can result
in the erroneous conclusion that the sequence variants
within the NUMT pseudogene are the cause of the disease
(26,27).
To address this problem, we have developed a MITOMAP
human NUMT database (25). By scanning the NUMT
sequences that encompass the same region as that of clinical
interest, the potential nDNA pseudogene variants can be
identiﬁed.
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The MITOMAP database currently encompasses over
5100 references. These pertain to the mtDNA sequence, seq-
uence variation and mitochondrial role in a wide variety of
diseases. This reference database is searchable by author
and subject word.
MITOMAP COMPUTATIONAL SYSTEM AND
DATABASE MAINTENANCE
All of the data for MITOMAP is now managed in Post-
greSQL (http://www.postgresql.org/), an open-source data-
base management system (i.e. DBMS) with object-relational
modeling capabilities. All programs are written in the Perl
programming language.
Data for MITOMAP are initially extracted by the database
curators and stored, formatted and screened in Excel spread-
sheets. Updated versions of the curated data are then periodi-
cally uploaded to the server, where Perl programs
implementing the ParseExcel and DBI modules are used to
parse the values from the spreadsheets and populate the
data structures implemented in PostgreSQL. Error screening
is performed both by the curator and by the population
programs.
The MITOMAP servers are located at the University of
California, Irvine, on a dual-processor server running RedHat
Linux as its operating system. This system is accessed
through a dynamic web interface using an Apache webserver.
DISCUSSION
By adding the mtDNA mutational tree, updating the depth
and breadth of the mtDNA disease mutation tables and creat-
ing a NUMT pseudogene sequence database, we have now
generated the informational infrastructure that will permit
MITOMAP to evolve from a simple factual database to an
intelligent analytical system. The sequential mutation
mtDNA phylogenetic tree places all of the factual informa-
tion about mtDNA sequence variation into an evolutionary
and functional context. This single integrated entity thus
automatically sorts mtDNA variants into ancient versus
recent mutations, deﬁnes the gene affected and provides pre-
liminary information on the potential functional implications
of the mutation.
From this foundation, MITOMAP is now poised to imple-
ment our much more powerful data integration and analysis
system, MITOMASTER. The MITOMAP-MITOMASTER
system will permit the user to up-load a new mtDNA sequen-
ce, and the system will automatically identify the sequence
variants relative to the rCRS, determine the mtDNA
haplogroup, indicate the potentially functional variants,
check for NUMT pseudogene variants and provide a list of
potential disease causing mutations. Hence MITOMAP-
MITOMASTER will soon be an important bioinformatics
tool in the analysis of human mtDNA sequence variation.
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